INCY - Incyte Corporation
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Data at the 2026 EADV Congress Underscore the Breadth of Incyte's Inflammation and Autoimmunity Portfolio.
The First Trust Large Cap Growth AlphaDEX ETF (FTC) was launched on 05/08/2007, and is a smart beta exchange traded fund designed to offer broad exposure to the Style Box - Large Cap Growth category of the market.
Incyte (NASDAQ: INCY) executives outlined a strategy centered on expanding its non-JAKAFI business, advancing a broader late-stage pipeline and preparing for the loss of exclusivity for JAKAFI after 2029. Chief Executive Officer Bill Meury said the company's pipeline has changed substantially over the past year, citing proof-of-concept data for its CALR antibody 989 in myelofibrosis and
/PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) today announced an expansion of its existing partnership with Incyte
Incyte NASDAQ: INCY executives outlined a strategy centered on expanding its non-JAKAFI business, advancing a broader late-stage pipeline and preparing for the loss of exclusivity for JAKAFI after 2029.
Incyte Corporation (INCY) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Integrated Wealth Concepts LLC trimmed its holdings in Incyte Corporation (NASDAQ: INCY) by 26.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,069 shares of the biopharmaceutical company's stock after selling 5,987 shares during the quarter. Integrated Wealth Concepts
Incyte's strong product demand and pipeline progress fuel its 23% YTD rally, but valuation and near-term earnings pressure temper the outlook.
Incyte Corporation (INCY) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Incyte Corporation (INCY) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Launched on May 8, 2007, the First Trust Large Cap Growth AlphaDEX ETF (FTC) is a passively managed exchange traded fund designed to provide a broad exposure to the Large Cap Growth segment of the US equity market.
Incyte Corporation is transitioning from a Jakafi-centric model to a diversified, multi-franchise biotech with several late-stage pipeline assets. 2Q26 results showed 17% underlying net sales growth, broad-based portfolio expansion, and strong operating leverage despite one-time Opzelura CMS benefits. INCY's pipeline maturity and upcoming 2H26 clinical readouts across dermatology, hematology, and oncology are pivotal for validating its multi-engine growth thesis.
Beacon Pointe Advisors LLC bought a new position in Incyte Corporation (NASDAQ: INCY) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 84,502 shares of the biopharmaceutical company's stock, valued at approximately $9,579,000. Several other large investors have also recently bought and
MONTREAL, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. ("Knight") (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today that it has submitted a supplemental application to ANVISA, the Brazilian health regulatory agency, seeking approval for an additional indication for MINJUVI® (tafasitamab) in combination with lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). The supplemental application for the additional indication was selected for review under Project Orbis.
Incyte (INCY) reported earnings 30 days ago. What's next for the stock?
Pre-Market Stock Futures: Futures are trading lower after a wild day on Wall Street, as stocks took off after Treasury Secretary Bessent announced the Treasury would double its current bond buyback, targeting 10- to 20-year and 20- to 30-year maturities. That sparked an initial big rally, which tapered by the close; still, all of the... Here Are Thursday's Top Wall Street Analyst Research Calls: Alphabet, Analog Devices, Crown Castle, ebay, EPR Properties, Etsy, Merck and Co., Shopify, TJX Companies, and More
MECHANICSBURG, Pa.--(BUSINESS WIRE)--The Global Vitiligo Foundation (GVF) proudly recognizes and supports Incyte's Moments of Clarity campaign, a powerful storytelling initiative that highlights the lived experiences of individuals with nonsegmental vitiligo. Through authentic patient narratives, the campaign closely aligns with GVF's mission to improve the quality of life for people affected by vitiligo through education, advocacy, and community connection. Moments of Clarity captures pivotal.
Biopharmaceutical company Incyte Corporation (INCY) gets Big Money support to gain 23% so far in 2026.
Cetera Investment Advisers trimmed its position in Incyte Corporation (NASDAQ: INCY) by 18.7% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,490 shares of the biopharmaceutical company's stock after selling 5,879 shares during the period. Cetera Investment Advisers' holdings in